AccessDX Holdings acquires 2bPrecise

Combined capabilities create industry’s most advanced precision medicine enablement solution

PITTSBURGH and HOUSTON – Aug. 25, 2021 – AccessDX Holdings, an international provider of advanced laboratory diagnostic solutions, has acquired 2bPrecise™ from Allscripts Healthcare Solutions. A recognized leader and innovator in healthcare informatics, 2bPrecise enables organizations to amplify their precision medicine strategies by delivering point-of-care insights so providers can identify patients at risk for heritable conditions, arrive at precise diagnoses more quickly and initiate optimal therapies more quickly.

2bPrecise will join the AccessDX portfolio of industry-leading diagnostics, software and services, including the MedTek21 software platform which facilitates diagnostic-based clinical decision support, compliance and program analytics for thousands of care organizations, patient groups and providers. The combined strengths of AccessDX and 2bPrecise ensure meaningful insights will be accessible within the clinical workflow of any EHR, while helping organizations streamline virtually all aspects of establishing and supporting precision medicine programs.

“We’re thrilled to welcome the 2bPrecise team and platform as we execute on our combined vision for democratizing the use, interpretation and delivery of advanced diagnostic solutions at the point of care,” said Joe Spinelli, SVP of Product & Strategy for AccessDX. “Combined, our worldwide organization will be able to accelerate the pace of innovation and best serve the needs of healthcare organizations that continue to expand their adoption of actionable precision medicine solutions.”

Utilization of genetic and genomic data is accelerating across nearly all clinical specialties, perhaps most notably in behavioral health/psychiatry, neonatology and pediatrics, oncology and cardiology. Providers can arrive at precise diagnoses faster and initiate effective treatments sooner when genetic and genomic information is available and actionable. Providers, payers and clinical organizations alike agree that the ability to seamlessly access information within their clinical workflow is key to precision-medicine success.

“AccessDX is a genuine leader in genomic information management. Our collective capabilities will serve as a force multiple for the practical utilization of precision medicine,” said Assaf Halevy, founder and CEO of 2bPrecise. “With a unified mission to drive dimensional change in healthcare, the combined talents and energy of 2bPrecise and AccessDX will compound acceleration in delivering on our vision of intelligent, personalized care for the good of healthcare organizations and the patients they serve.”

About AccessDX Laboratory

AccessDX Laboratory is a CLIA-certified, CAP-accredited and NYCQ diagnostic laboratory dedicated to providing clinical insights that improve patient outcomes. AccessDX diagnostic solutions include COVID- 19 testing, pharmacogenomic (PGX) testing, cancer genomic (CGX) testing, respiratory pathogen panels and a wide range of other clinical laboratory services. AccessDX diagnostic and software solutions are currently trusted by thousands of clinical providers in health systems nationwide. For more information, please visit

About MedTek21

MedTek21 is a real-time population health and medication risk management platform that brings personalized drug-to-gene monitoring to every patient. The company’s software-based platform works alongside existing medical record systems to continuously monitor, proactively identify, and help remediate potential medication risks. MedTek21’s mobile-based medication risk alerting, drug lookup tools, actionable reporting, and clinical support staff enable both patients and their care providers with better real-time decision making. MedTek21 is being used to positively impact outcomes and lower care costs for tens of thousands of patients across general, acute, and chronic populations. For more information on the MedTek21, please visit

About 2bPrecise

The 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. It brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for genomic workflows and decision-making, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.

Media Contact:

Emily Wisner
Account Executive, Aria Marketing (for 2bPrecise)